Concord Biotech Ltd (CONCORDBIO) — shareholding pattern, promoter holding, financials and share price
About Concord Biotech Ltd (CONCORDBIO)
Concord Biotech Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as CONCORDBIO and on the BSE under scrip code 543960. Its ISIN is INE338H01029.
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology. [1]
Concord Biotech Limited is an R&D-driven biopharmaceutical company that develops and manufactures fermentation-based active pharmaceutical ingredients (APIs), finished formulations and CDMO services, serving 70+ countries including regulated markets and maintaining over 140 DMFs and significant fermentation capacity across multiple Gujarat facilities.
Q3 FY26 performance showed revenue improvement with consolidated quarterly revenue of INR 278 crore (up 14% YoY) driven by a 24% jump in API sales, while 9MFY26 revenue remained lower at INR 729 crore due to timing-related headwinds and geopolitical/tariff disruptions which management describes as temporary.
Listed peers in Pharmaceuticals: Jubilant Pharmova Ltd, Alivus Life Sciences Ltd, Corona Remedies Ltd, Marksans Pharma Ltd, Shilpa Medicare Ltd, Viyash Scientific Ltd.
Valuation & Returns
10 Jul 2026At ₹1,300.05 a share on 10 Jul 2026, Concord Biotech Ltd (CONCORDBIO) was valued at a price-to-earnings ratio of 52.47x against an industry P/E of 36.41x and a price-to-book of 7.5x on a book value of ₹173.27 per share as of Mar 2025. Solomo computes return on equity of 14.3% and return on capital employed of 19% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 52.47x
- Industry P/E
- 36.41x
- P/B
- 7.5x
- EPS (TTM)
- ₹24.78
- Book value / share
- ₹173.27
- ROE
- 14.3%
- ROCE
- 19%
- ROA
- 12.74%
- Debt / equity
- 0x
- Dividend yield
- 0.82%
- EBITDA margin
- 39.76%
- 52-week range
- ₹987.05 – ₹1,979.2
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Concord Biotech Ltd (CONCORDBIO) reported revenue of ₹1,055 crore, net profit of ₹259 crore and earnings per share of ₹24.94. That compares with revenue of ₹1,200 crore and net profit of ₹372 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹326 crore and net profit ₹88 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 713 | 853 | 1,017 | 1,200 | 1,055 |
| Net profit (₹ cr) | 175 | 240 | 308 | 372 | 259 |
| EPS (₹) | 183.93 | 22.95 | 29.45 | 35.52 | 24.94 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 11.33% | 7.34% | -12.10% |
| Profit growth | 2.27% | 3.40% | -30.25% |
| Stock price CAGR | - | - | -27% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 44.08% of Concord Biotech Ltd (CONCORDBIO) (unchanged from the previous quarter), foreign institutional investors (FII) hold 7.52% and domestic institutional investors (DII) hold 9.36%. Market capitalisation was ₹13,601 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2023.
Largest disclosed public shareholders in Jun 2026: Aryavir Jhunjhunwala Discretionary Trust 8.03%, Aryaman Jhunjhunwala Discretionary Trust 8.03%, Nishtha JhunjhunwalaDiscretionary Trust 8.03%, Government Pension Fund Global 2.95%, Tata Aia Life Insurance Co Ltd Unit Linked Multi Cap Fund 2.48%, 1575773 Ontario Inc 2%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 44.08% | - | 7.52% | 9.36% | 55.92% |
| Mar 2026 | 44.08% | - | 7.8% | 9.22% | 55.92% |
| Dec 2025 | 44.08% | - | 7.58% | 9.58% | 55.92% |
| Sep 2025 | 44.08% | - | 8.03% | 9.55% | 55.92% |
| Jun 2025 | 44.08% | - | 9.11% | 8.87% | 55.92% |
| Mar 2025 | 44.08% | - | 9.35% | 9.16% | 55.92% |
| Dec 2024 | 44.08% | - | 8.33% | 9.66% | 55.92% |
| Sep 2024 | 44.08% | - | 8.1% | 9.89% | 55.92% |